Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature.
OBJECTIVE
To report a case of an uncommon and up to date unpublished peracute and overwhelming muscle pain following administration of ciprofloxacin.


METHODS
A 58-year-old male developed fulminating musculoskeletal pain associated with third-time exposure to ciprofloxacin administered for treatment of chronic otitis media. Symptoms resolved slowly after intense combined analgetic therapy and cessation of ciprofloxacin therapy. 24 h after ciprofloxacin discontinuation the symptoms had completely disappeared and no more analgetic treatment was needed. Laboratory values, especially muscle enzymes, did not reveal any pathological pattern. The patient's past medical history highlighted reproducible side effects with both systemic and local administration of ciprofloxacin including milder symptoms of the musculoskeletal system.


CONCLUSIONS
Common side effects of fluoroquinolones include gastrointestinal, central nervous and allergic reactions, but also more uncommon reactions such as tendonitis and rhabdomyolysis. In our case, there had been no signs of rhabdomyolysis. Besides an elevated IgE level no clinical signs of a true anaphylactic reaction associated with release of mast cell mediators had been observed. A pharmacokinetic interaction between ciprofloxacin and the patient's comedication carbamazepine is unlikely to be the responsible mechanism, since fluoroquinolones inhibit cytochrome P450 isoenzyme CYP1A2 but not CYP3A4 which metabolizes carbamazepine.


CONCLUSIONS
To our knowledge, this is the first report describing fulminating musculoskeletal pain following administration of ciprofloxacin without any signs of rhabdomyolysis. Physicians should notice that there is a variety of adverse reactions of this usually well-tolerated agent and they should be aware of unusual complaints of their patients who receive fluoroquinolone treatment.
Eisele
S
S
Department of Gastroenterology, Charité Campus Benjamin Franklin, Berlin, Germany.
Garbe
E
E
Zeitz
M
M
Schneider
T
T
Somasundaram
R
R
D000208:Acute Disease; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000009:adverse effects* / Q000627:therapeutic use; D004630:Emergencies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced* / Q000188:drug therapy; D010033:Otitis Media / Q000188:drug therapy; D010146:Pain / Q000139:chemically induced* / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin